Company news
Larimar Therapeutics, Inc. (NASDAQ:LRMR) news
Larimar Therapeutics, Inc. news releases on 6ix. Latest, Sep 14, 2022: Larimar Therapeutics Announces $70 Million Underwritten Offering
Press releases — page 2
Larimar Therapeutics Announces $70 Million Underwritten Offering
September 13, 2022
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
August 10, 2022
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
July 27, 2022
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
June 27, 2022
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
June 1, 2022
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
May 18, 2022
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
May 11, 2022
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
March 24, 2022
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
February 13, 2022
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
November 11, 2021
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
August 18, 2021
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
August 11, 2021
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
May 24, 2021
Larimar Therapeutics Announces $95 Million Private Placement Financing
May 20, 2021
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
May 19, 2021
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
May 10, 2021
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
May 9, 2021
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
March 3, 2021
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
December 7, 2020
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
November 9, 2020
Larimar Therapeutics Announces Formation of Scientific Advisory Board
October 12, 2020
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
August 10, 2020
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
July 27, 2020
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
July 19, 2020